Breast Cancer
Conditions
Keywords
breast cancer, adjuvant chemotherapy, trastuzumab, anthracycline
Brief summary
Most of the published data support the preferential use of an anthracycline-containing adjuvant regimen for individuals with HER2-positive tumors. Concurrent anthracyclines and trastuzumab, however, are contraindicated due to the observation of unacceptably high rates of cardiotoxicity in a large randomized trial in the metastatic setting. However, in neoadjuvant setting, trastuzumab concurrently with an anthracycline-containing chemotherapy regimen had shown high pathological complete response (pCR) and very low cardiotoxicity. All large adjuvant trials have evaluated only the sequential strategy of administering anthracyclines and trastuzumab. The safety and efficacy of trastuzumab concurrently with an anthracycline-containing chemotherapy regimen has never been evaluated in adjuvant setting. Given the similar patients characteristics, the investigators hypothesize that trastuzumab concurrently with an anthracycline-containing chemotherapy regimen would not increase cardiotoxicity but efficacy.
Interventions
DRUGconcurrent
Trastuzumab will be administered concurrently with any anthracycline-containing regimen for breast cancer adjuvant chemotherapy. Trastuzumab will be given intravenously 8mg/kg loading dose, followed by 6mg/kg every 3 weeks for one year.
DRUGsequential
Trastuzumab will be administered sequentially to any anthracycline-containing regimen for breast cancer adjuvant chemotherapy. Trastuzumab will be given intravenously 8mg/kg loading dose, followed by 6mg/kg every 3 weeks for one year.
Sponsors
Peking Union Medical College Hospital
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
FEMALE
Age
18 Years to 70 Years
Healthy volunteers
No
Inclusion criteria
* Written informed consent. * Histological diagnosis of operable invasive adenocarcinoma of the breast. Tumours must be HER2 positive. Time window between surgery and study randomization must be less than 60 days. * Surgery must consist of mastectomy or conservative surgery with axillary lymph node dissection or sentinel lymph node biopsy. Margins free of disease and ductal carcinomas in situ (DCIS) are required. Lobular carcinoma is not considered a positive margin. * Positive axillary lymph nodes defined as at least 1 out of 10 nodes with presence of disease. If sentinel node technique is used, sentinel node can be the only node affected. * Status of hormone receptors in primary tumour must be available before the end of adjuvant chemotherapy. * Patients must not present evidence of metastatic disease. Status of HER2 in primary tumour, known before randomization. Patients with immune histochemistry (IHC) 3+ are eligible. For patients with ICH 2+, fluorescence in situ hybridization (FISH) is mandatory and result must be positive. * Age \>= 18 and \<= 70 years old. * Performance status (Karnofsky index) \>= 80. * Normal electrocardiogram (EKG) in the 12 weeks prior to randomization. * Cardiac function monitored by left ventricular ejection fraction (LVEF) must be \>= 55%. * Laboratory results (within 14 days prior to randomization): * Hematology: neutrophils \>= 1.5 x 10\^9/l; platelets \>= 100 x 10\^9/l; hemoglobin \>= 10 mg/dl; * Hepatic function: total bilirubin \<= 1 upper normal limit (UNL); SGOT and SGPT \<= 2.5 UNL; alkaline phosphatase \<= 2.5 UNL. If values of SGOT and SGPT \> 1.5 UNL are associated to alkaline phosphatase \> 2.5 UNL, patient is not eligible; * Renal function: creatinine \<= 175 mmol/l (2 mg/dl); creatinine clearance \>= 60 ml/min; * Complete stage workup during the 12 weeks prior to randomization (mammograms are allowed within a 20 week window). All patients must have a bilateral mammogram, thorax x-ray, abdominal echography and/or computed tomography (CT)-scan. If bone pain, and/or alkaline phosphatase elevation, a bone scintigraphy is mandatory. This test is recommended for all patients. Other tests: as clinically indicated. * Patients able to comply with treatment and study follow-up. * Negative pregnancy test done in the 14 prior days to randomization.
Exclusion criteria
* Prior systemic therapy for breast cancer. * Prior therapy with anthracyclines or trastuzumab for any malignancy. * Prior radiotherapy for breast cancer. * Bilateral invasive breast cancer. * Pregnant or lactating women. Adequate contraceptive methods must be used during chemotherapy and hormone therapy treatments. * Any M1 tumor. * HER2 negative breast cancer (IHC 0or 1+ or negative FISH result). * Pre-existing grade \>= 2 motor or sensorial neurotoxicity (National Cancer Institute Common Toxicity Criteria version 2.0 \[NCI CTC v-2.0\]). * Any other serious medical pathology, such as congestive heart failure; unstable angina; history of myocardial infarction during the previous year; uncontrolled HA or high risk arrhythmias. * left ventricular ejection fraction (LVEF) less than 55%. * History of neurological or psychiatric disorders, which could preclude the patients from free informed consent. * Active uncontrolled infection. * Active peptic ulcer; unstable diabetes mellitus. * Previous or current history of neoplasms different from breast cancer, except for skin carcinoma, cervical in situ carcinoma, or any other tumour curatively treated and without recurrence in the last 10 years; ductal in situ carcinoma in the same breast; lobular in situ carcinoma. * Chronic treatment with corticosteroids. * Contraindications for corticosteroid administration. * Concomitant treatment with raloxifene, tamoxifen or other selective estrogen receptor modulators (SERMs), either for osteoporosis treatment or for prevention. These treatments must stop before randomisation. * Concomitant treatment with other investigational products; participation in other clinical trials with a non-marketed drug in the 20 previous days before randomization. * Concomitant treatment with another therapy for cancer. * Males.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| cardiotoxicity | 2 years | the heart failure rate will be compared at 2 years, and left ventricular ejection fraction (LVEF) changes will be monitored during 3, 6, 9, 12, 24 months after firs dose of drug administration |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| disease-free survival | 3 years and 5 years | local recurrence, regional recurrence, contralateral breast recurrence, distant metastasis, death |
| Overall survival | 5 years | — |
| Adverse event rate (CTCAE v. 3.0) | 2 years | Adverse events other than cardiotoxicity |
Countries
China
Outcome results
None listed